Companies › Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
3 active drug programs in 20 registered trials: 16 Phase 2, 3 Phase 3, 1 Phase 1; Oncology, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Abiraterone Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist; Steroid 5-alpha-reductase inhibitor | CYP17A1, AR, SRD5A1, SRD5A2, SRD5A3 | Phase 2 | Prostate Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC); Castration Levels of Testosterone; Advanced Prostate Adenocarcinoma … | Nov 2026 |
| Raloxifene Estrogen receptor beta modulator; Estrogen receptor modulator | ESR2, ESR1 | Phase 2 | Breast Cancer; BPH (Benign Prostatic Hyperplasia); Brain Tumor | Dec 2026 |
| CEA protein antigen plus BCG Vaccine Mix CEA antigen with trained immunity via BCG; APCs process CEA antigen into peptide fragments | CEA | Phase 1 | Rectal Cancer | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06173362 | Abiraterone | Phase 2 | Advanced Prostate Adenocarcinoma | Oncology | Nov 2026 |
| NCT03348670 | Abiraterone | Phase 2 | Prostate Cancer | Oncology | Nov 2026 |
| NCT02403505 | CEA protein antigen plus BCG Vaccine Mix | Phase 1 | Rectal Cancer | Oncology | Nov 2026 |
| NCT03903835 | Abiraterone | Phase 3 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Oncology | Dec 2026 |
| NCT06655259 | Abiraterone | Phase 2 | Metastatic Prostate Cancer | Oncology | Dec 2026 |
| NCT06062810 | Raloxifene | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT07299292 | Abiraterone | Phase 2 | Prostate Cancer (Diagnosis) | Oncology | Dec 2026 |
| NCT04748042 | Abiraterone | Phase 2 | Prostate Cancer | Oncology | May 2027 |
| NCT05189457 | Abiraterone | Phase 2 | Prostate Cancer | Oncology | Jul 2027 |
| NCT06971211 | Abiraterone | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Oncology | Oct 2027 |
| NCT06832774 | Abiraterone | Phase 2 | Prostate Cancer Metastatic Disease | Oncology | Dec 2027 |
| NCT07815522 | Abiraterone | Phase 2 | Salivary Gland Carcinoma | Oncology | Oct 2028 |
| NCT06944145 | Raloxifene | Phase 2 | BPH (Benign Prostatic Hyperplasia) | Genitourinary | Jun 2029 |
| NCT07751133 | Abiraterone | Phase 3 | Prostate Cancer | Oncology | Aug 2029 |
| NCT07470606 | Raloxifene | Phase 2 | Brain Tumor | Oncology | Jul 2030 |
| NCT00268476 | Abiraterone | Phase 2 | Prostate Cancer | Oncology | Dec 2030 |
| NCT05404139 | Abiraterone | Phase 2 | Metastatic Prostate Cancer | Oncology | Feb 2031 |
| NCT03678025 | Abiraterone | Phase 3 | Castration Levels of Testosterone | Oncology | Apr 2033 |
| NCT07237269 | Abiraterone | Phase 2 | Prostate Cancer | Oncology | Apr 2033 |
| NCT06818682 | Abiraterone | Phase 2 | Prostate Carcinoma | Oncology | Jan 2035 |
AstraZeneca Pfizer Astellas Roche Novartis Johnson & Johnson (Janssen) Sun Pharmaceutical Industries Azure Biotech LeonaBio Alessa Therapeutics
Alpheus Medical Beijing Yongtai Ruike Biotechnology Company Hebei Senlang Biotechnology Neuboron Bio-SciTech Hrain Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.